Am J Perinatol 2021; 38(05): 463-468
DOI: 10.1055/s-0039-1698456
Original Article

Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit

Diane Song
1   Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio
,
Jacqueline Magers
1   Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio
,
Mahmoud Abdel-Rasoul
2   Center for Biostatistics, Ohio State University Medical Center, Biostatistics Resource at Nationwide Children's Hospital, Columbus, Ohio
,
Pavel Prusakov
1   Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio
› Author Affiliations

Abstract

Objective This article evaluates the efficacy of enoxaparin when targeting anti-factor Xa levels of 0.5 to 1 units per milliliter in the neonatal intensive care unit.

Study Design This is a retrospective chart review of 45 neonates receiving enoxaparin for the treatment of venous thromboembolism. Enoxaparin dosing and corresponding anti-factor Xa levels were collected. Time to resolution of clot was confirmed by imaging and compared between clots in various locations.

Results The median time to clot resolution was 76 days (interquartile range 40–91 days). Clot location, postnatal age, and sex at the clot onset were significantly associated with time to clot resolution in a multivariable Cox model (p-value: 0.03, 0.03, and < 0.01, respectively). Of the 54 patients analyzed for safety, 5 patients (9.3%) experienced bleeding events resulting in the discontinuation of enoxaparin.

Conclusion Based on our findings, 50% of all patients evaluated, regardless of thrombus location, achieved resolution within the first 76 days of therapy. Clots located in the extremities tended to resolve sooner, hence earlier reimaging should be considered.



Publication History

Received: 17 June 2019

Accepted: 03 September 2019

Article published online:
26 October 2019

© 2019. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004; 145 (04) 563-565
  • 2 Chalmers EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2006; 118 (01) 3-12
  • 3 Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatal Med 2006; 11 (03) 198-206
  • 4 Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009; 23 (05) 225-229
  • 5 Monagle P, Chan AKC, Goldenberg NA. et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e737S-e801S
  • 6 Malowany JI, Monagle P, Knoppert DC. et al; Canadian Paediatric Thrombosis and Hemostasis Network. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res 2008; 122 (06) 826-830
  • 7 Hirsh J, Warkentin TE, Shaughnessy SG. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1, Suppl): 64S-94S
  • 8 Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 2010; 29 (02) 233-240
  • 9 Revel-Vilk S. The conundrum of neonatal coagulopathy. Hematology (Am Soc Hematol Educ Program) 2012; 2012 (01) 450-454
  • 10 Brown JB, Cohen MJ, Minei JP. et al; Inflammation and the Host Response to Injury Investigators. Characterization of acute coagulopathy and sexual dimorphism after injury: females and coagulopathy just do not mix. J Trauma Acute Care Surg 2012; 73 (06) 1395-1400
  • 11 Ho P, Ng C, Rigano J. et al. Significant age, race and gender differences in global coagulation assays parameters in the normal population. Thromb Res 2017; 154: 80-83
  • 12 Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128 (03) 313-318
  • 13 Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy 2007; 27 (09) 1263-1271
  • 14 Sanchez de Toledo J, Gunawardena S, Munoz R. et al. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?. Cardiol Young 2010; 20 (02) 138-143
  • 15 Dallman PR. Anemia of prematurity. Annu Rev Med 1981; 32 (01) 143-160